Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Sweeting

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Pharmaceutical Statistics|October 27, 2024
Treatment Effect Measures Under Nonproportional HazardsDan Jackson, Michael Sweeting, Rose Baker
Pharmaceutical Statistics|June 5, 2026
CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized TrialsFanni Zhang, Kristine Broglio, Michael Sweeting, et al.
Journal of the Royal Statistical Society. Series C, Applied Statistics|November 14, 2013
Fully Bayesian hierarchical modelling in two stages, with application to meta-analysisDavid Lunn, Jessica Barrett, Michael Sweeting, et al.
Biometrics|February 24, 2025
Potential outcome simulation for efficient head-to-head comparison of adaptive dose-finding designsMichael Sweeting, Daniel Slade, Dan Jackson, et al.
Thoracic Cancer|January 14, 2025
Long-Term Real-World Survival of Immunotherapy Compared to Chemotherapy for Metastatic Nonsmall Cell Lung Cancer: A Propensity Score-Matched AnalysisKun Kim, Michael Sweeting, Linus Jönsson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 12, 2024
General Population Mortality Adjustment in Survival Extrapolation of Cancer Trials: Exploring Plausibility and Implications for Cost-Effectiveness Analyses in HER2-Positive Breast Cancer in SwedenKun Kim, Michael Sweeting, Nils Wilking, et al.
Diagnostic and Prognostic Research|June 1, 2022
A scoping methodological review of simulation studies comparing statistical and machine learning approaches to risk prediction for time-to-event dataHayley Smith, Michael Sweeting, Tim Morris, et al.
Acta Oncologica (Stockholm, Sweden)|October 27, 2025
Cost of treatment of metastatic non-small lung cancer in Sweden, 2011-2023Kun Kim, Michael Sweeting, Nils Wilking, et al.
BMC Cancer|October 6, 2022
Glycosylated haemoglobin and prognosis in 10,536 people with cancer and pre-existing diabetes: a meta-analysis with dose-response analysisSuping Ling, Michael Sweeting, Francesco Zaccardi, et al.
Cancers|November 11, 2022
The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS StatusHeather Poad, Sam Khan, Lorna Wheaton, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Pharmaceutical Statistics|October 27, 2024
Treatment Effect Measures Under Nonproportional HazardsDan Jackson, Michael Sweeting, Rose Baker
Pharmaceutical Statistics|June 5, 2026
CUI-MET: A Clinical Utility Index Based Analysis and Decision Framework for Dose Optimization in Multiple-Dose, Multiple-Outcome Randomized TrialsFanni Zhang, Kristine Broglio, Michael Sweeting, et al.
Journal of the Royal Statistical Society. Series C, Applied Statistics|November 14, 2013
Fully Bayesian hierarchical modelling in two stages, with application to meta-analysisDavid Lunn, Jessica Barrett, Michael Sweeting, et al.
Biometrics|February 24, 2025
Potential outcome simulation for efficient head-to-head comparison of adaptive dose-finding designsMichael Sweeting, Daniel Slade, Dan Jackson, et al.
Thoracic Cancer|January 14, 2025
Long-Term Real-World Survival of Immunotherapy Compared to Chemotherapy for Metastatic Nonsmall Cell Lung Cancer: A Propensity Score-Matched AnalysisKun Kim, Michael Sweeting, Linus Jönsson, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|September 12, 2024
General Population Mortality Adjustment in Survival Extrapolation of Cancer Trials: Exploring Plausibility and Implications for Cost-Effectiveness Analyses in HER2-Positive Breast Cancer in SwedenKun Kim, Michael Sweeting, Nils Wilking, et al.
Diagnostic and Prognostic Research|June 1, 2022
A scoping methodological review of simulation studies comparing statistical and machine learning approaches to risk prediction for time-to-event dataHayley Smith, Michael Sweeting, Tim Morris, et al.
Acta Oncologica (Stockholm, Sweden)|October 27, 2025
Cost of treatment of metastatic non-small lung cancer in Sweden, 2011-2023Kun Kim, Michael Sweeting, Nils Wilking, et al.
BMC Cancer|October 6, 2022
Glycosylated haemoglobin and prognosis in 10,536 people with cancer and pre-existing diabetes: a meta-analysis with dose-response analysisSuping Ling, Michael Sweeting, Francesco Zaccardi, et al.
Cancers|November 11, 2022
The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS StatusHeather Poad, Sam Khan, Lorna Wheaton, et al.
Pageof 5